PropertyValue
?:abstract
  • Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SARS-CoV-2 mAbs. While many candidates are in preclinical development, we focus here on anti-SARS-CoV-2 neutralizing mAbs (or mAb cocktails) that represent the late-stage clinical pipeline, i.e., those currently in Phase 2 or Phase 3 clinical trials. We describe the structure, mechanism of action, and ongoing trials for VIR-7831, LY-CoV555, LY-CoV016, BGB-DXP593, REGN-COV2, and CT-P59. We speculate also on the next generation of these mAbs.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1080/19420862.2020.1854149
?:journal
  • mAbs
?:license
  • cc-by-nc
?:pdf_json_files
  • document_parses/pdf_json/8143ffb08c8376e638902c71fdf3508237f46574.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7755170.xml.json
?:pmcid
?:pmid
?:pmid
  • 33319649.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
?:type
?:year
  • 2020-12-15

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/glmp1uz1>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/glmp1uz1>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all